What is Fios Genomics?
Fios Genomics operates as a specialized bioinformatics service provider, bridging the gap between complex biological data and actionable research outcomes. The company offers a comprehensive suite of analytical solutions, including gene expression profiling, single-cell analysis, and proteomics. By serving a sophisticated clientele that spans pharmaceutical giants, contract research organizations (CROs), and academic institutions, Fios Genomics plays a critical role in accelerating the drug discovery and development lifecycle. Their commitment to precision and scientific rigor has established them as a vital partner for organizations seeking to validate findings and optimize research breakthroughs. Furthermore, the company distinguishes itself through a commitment to sustainability, operating as an SME Climate Hub participant, which aligns its operational ethos with modern environmental, social, and governance (ESG) standards.
How much funding has Fios Genomics raised?
Fios Genomics has raised a total of $2.8M across 4 funding rounds:
Private Equity
$817K
Series B
$710K
Other Financing Round
$795K
Series C
$509K
Private Equity (2011): $817K with participation from Scottish Enterprise and Archangel Informal Investment
Series B (2011): $710K led by TRICAPITAL and Archangels
Other Financing Round (2013): $795K supported by Archangel and Tweed Renaissance Investors Capital
Series C (2014): $509K featuring Tweed Renaissance Investors Capital
Key Investors in Fios Genomics
Scottish Enterprise
Founded in 1991, Scottish Enterprise is a national economic development agency and a non-departmental public body of the Scottish Government focused on fostering regional innovation.
Tweed Renaissance Investors Capital
TRI Cap is a business angel syndicate based in the Scottish Borders that specializes in providing growth capital to emerging enterprises with high potential.
Archangel Informal Investment
A prominent investment group focused on supporting early-stage and growth-oriented companies through strategic capital and mentorship.
What's next for Fios Genomics?
Looking ahead, Fios Genomics is poised to leverage its recent capital influx to enhance its computational infrastructure and broaden its service offerings. As the demand for high-throughput genomic data analysis continues to surge, the company is expected to focus on integrating advanced machine learning models to further refine its predictive capabilities. Strategic priorities likely include the expansion of its international market presence and the deepening of its collaborative research partnerships. By focusing on the intersection of bioinformatics, drug discovery, and sustainable research practices, Fios Genomics is strategically aligned to capture significant market share in the evolving life sciences sector. The firm's ability to translate raw biological data into high-fidelity insights remains its primary competitive advantage as it enters this next phase of enterprise-level scaling.
See full Fios Genomics company page
